Literature DB >> 19081768

Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

Annette Bruchfeld1, Juan J Carrero, Abdul R Qureshi, Bengt Lindholm, Peter Barany, Olof Heimburger, Maowen Hu, Xinchun Lin, Peter Stenvinkel, Edmund J Miller.   

Abstract

Chronic kidney disease (CKD) carries an increased risk of cardiovascular disease (CVD). Macrophage migration inhibiting factor (MIF) is a proinflammatory cytokine implicated in the pathogenesis of sepsis, autoimmune disease, atherogenesis, and plaque instability, and is a known cardiac depressant. This post-hoc, cross-sectional study examined whether MIF serum concentrations are elevated in CKD patients. Our study included CKD 3-5 patients with moderate to severe renal dysfunction (n = 257) (mean age SD; 55 +/- 12 years) and 53 controls (60 +/- 12 years). Serum MIF concentrations, measured by enzyme-linked immunosorbent assay (ELISA), were studied in relation to glomerular filtration rate (GFR), presence of CVD, outcome and inflammatory and oxidative stress markers. MIF was significantly elevated in CKD patients compared with controls (CKD: median 676 [range 118-8275 pg/mL] controls: 433 [142-4707] pg/mL; P = 0.008). MIF was also associated with 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels (rho = 0.26; P = 0.001), a marker of oxidative stress, and ICAM-1 levels (rho = 0.14; P = 0.02), a marker of endothelial activation. However, the elevated MIF concentrations were neither correlated with glomerular filtration rate (GFR) nor inflammatory markers such as CRP, IL-6, and TNF. When combining MIF and IL-6 as a marker of inflammation, a significant increase in risk for CVD was found, but when analyzing all-cause mortality, this did not differ significantly with regard to mortality from inflamed patients with low MIF levels. The data suggest that increased serum MIF levels found in CKD is not caused primarily by poor renal function, but is associated with markers of oxidative stress and endothelial activation and may play a role in vascular disease associated with CKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19081768      PMCID: PMC2600496          DOI: 10.2119/molmed.2008.00109

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  25 in total

Review 1.  Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.

Authors:  Peter Stenvinkel; Roberto Pecoits-Filho; Bengt Lindholm
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

Review 2.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

3.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction.

Authors:  J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1966-07       Impact factor: 11.205

4.  Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection.

Authors:  F G Brown; D J Nikolic-Paterson; S J Chadban; J Dowling; M Jose; C N Metz; R Bucala; R C Atkins
Journal:  Transplantation       Date:  2001-06-27       Impact factor: 4.939

5.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.

Authors:  P Stenvinkel; O Heimbürger; F Paultre; U Diczfalusy; T Wang; L Berglund; T Jogestrand
Journal:  Kidney Int       Date:  1999-05       Impact factor: 10.612

6.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

7.  Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients.

Authors:  Vincenzo Panichi; Umberto Maggiore; Daniele Taccola; Massimiliano Migliori; Giovanni Manca Rizza; Cristina Consani; Alessio Bertini; Stefano Sposini; Rafael Perez-Garcia; Paolo Rindi; Roberto Palla; Ciro Tetta
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

8.  Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.

Authors:  B Descamps-Latscha; A Herbelin; A T Nguyen; P Roux-Lombard; J Zingraff; A Moynot; C Verger; D Dahmane; D de Groote; P Jungers
Journal:  J Immunol       Date:  1995-01-15       Impact factor: 5.422

9.  Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice.

Authors:  Andreas Schober; Jürgen Bernhagen; Michael Thiele; Ute Zeiffer; Sandra Knarren; Marion Roller; Richard Bucala; Christian Weber
Journal:  Circulation       Date:  2003-12-22       Impact factor: 29.690

10.  Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.

Authors:  C A Wijbrandts; S I van Leuven; H D Boom; D M Gerlag; E G S Stroes; J J P Kastelein; P P Tak
Journal:  Ann Rheum Dis       Date:  2008-08-22       Impact factor: 19.103

View more
  27 in total

Review 1.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

2.  MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome.

Authors:  Eva Cuzzoni; Raffaella Franca; Sara De Iudicibus; Annalisa Marcuzzi; Marianna Lucafò; Marco Pelin; Diego Favretto; Elena Monti; William Morello; Luciana Ghio; Claudio La Scola; Francesca Mencarelli; Andrea Pasini; Giovanni Montini; Giuliana Decorti; Gabriele Stocco
Journal:  Eur J Clin Pharmacol       Date:  2019-08-28       Impact factor: 2.953

3.  Macrophage Migration Inhibitory Factor: A Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1-p38-Xanthine Oxidoreductase-Dependent Cigarette Smoke-Induced Apoptosis.

Authors:  Jonathan Fallica; Lidenys Varela; Laura Johnston; Bo Kim; Leonid Serebreni; Lan Wang; Mahendra Damarla; Todd M Kolb; Paul M Hassoun; Rachel Damico
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

Review 4.  The role of ions, heavy metals, fluoride, and agrochemicals: critical evaluation of potential aetiological factors of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) and recommendations for its eradication.

Authors:  Sunil J Wimalawansa
Journal:  Environ Geochem Health       Date:  2015-10-13       Impact factor: 4.609

5.  Tangshen formula improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-κB pathway.

Authors:  Yue-Guang Du; Ke-Na Zhang; Zong-Lei Gao; Fengjiao Dai; Xi-Xi Wu; Ke-Fu Chai
Journal:  Exp Ther Med       Date:  2017-12-12       Impact factor: 2.447

6.  Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension.

Authors:  Yinzhong Zhang; Arunabh Talwar; Donna Tsang; Annette Bruchfeld; Ali Sadoughi; Maowen Hu; Kennedy Omonuwa; Kai Fan Cheng; Yousef Al-Abed; Edmund J Miller
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

7.  Vascular endothelial growth factor-A, matrix metalloproteinase-1, and macrophage migration inhibition factor changes in the porcine remnant kidney model: evaluation by magnetic resonance imaging.

Authors:  Sanjay Misra; Khamal D Misra; James F Glockner
Journal:  J Vasc Interv Radiol       Date:  2010-07       Impact factor: 3.464

8.  [Serum-based biomarkers for psychiatric disorders].

Authors:  S Bahn; E Schwarz
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

9.  Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Authors:  Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-25       Impact factor: 4.553

10.  A role for NRAGE in NF-kappaB activation through the non-canonical BMP pathway.

Authors:  Nicholas Matluk; Jennifer A Rochira; Aldona Karaczyn; Tamara Adams; Joseph M Verdi
Journal:  BMC Biol       Date:  2010-01-25       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.